Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Preventing Skeletal-Related Events in Breast Cancer

January 22nd 2014

Chemotherapeutics in Metastatic Breast Cancer

January 22nd 2014

CDK4/6 Inhibitors in Metastatic Breast Cancer

January 22nd 2014

Next Steps for Everolimus in Metastatic Breast Cancer

January 22nd 2014

Upfront Treatment of HR-Positive MBC

January 22nd 2014

Case Study: HER2-Positive Oligometastatic Breast Cancer

January 22nd 2014

Phase III Clinical Trials in HER2-Positive Breast Cancer

January 22nd 2014

Novel Drug Development in Breast Cancer

January 22nd 2014

Role of Lapatinib in HER2-Positive Breast Cancer

January 22nd 2014

Recommendations for Optimal HER2 Testing in Breast Cancer

January 22nd 2014

T-DM1 in HER2-Positive Metastatic Breast Cancer

January 22nd 2014

PIK3CA Mutations in HER2-Positive Breast Cancer

January 22nd 2014

Frontline Pertuzumab for Metastatic Breast Cancer

January 22nd 2014

Treating Low-Risk HER2-Positive Breast Cancer

January 22nd 2014

Overview of HER2-Targeted Therapies in Breast Cancer

January 22nd 2014

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Dr. Nagendran on Family History, BRCA Status, and Risk

January 20th 2014

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.

NewLink Genetics Pursues Dual Cancer Immunotherapy Platforms

January 20th 2014

Harnessing multiple components of the immune system to fight cancer is the focus of NewLink Genetics' clinical pipeline.

Kris Provides Insight Into New Drugs for Lung Cancer

January 16th 2014

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Dr. Piperdi on Immunotherapy in Lung Cancer

January 15th 2014

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.